“…The flowchart of the patient selection is shown in Figure 4; 19 studies with 21 cases fulfilled these criteria. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] Table 1 summaries the key information in these articles. The mean age of the previously reported patients with pulmonary angiosarcoma was 56.2 years, and in our cases, it was 64 years (range 54-74 years).…”
Pulmonary artery angiosarcoma is a rare malignant vascular tumor with an aggressive clinical course and a poor prognosis. Hemoptysis and shortness of breath have been reported as common clinical presentations. The exact clinicopathology is unknown. A tissue specimen obtained by percutaneous fine-needle aspiration cytology or open/thoracoscopic biopsy can confirm the diagnosis based on histopathological and immunohistochemical features. The differential diagnosis includes pulmonary thromboembolism, vascular malformations, and lung carcinoma. There is a paucity of literature describing this tumor, with only a few case reports available. There is also a lack of standardized guidelines for management, which further worsens the survival outcome. We report 3 cases of pulmonary artery angiosarcoma and review the recent literature.
“…The flowchart of the patient selection is shown in Figure 4; 19 studies with 21 cases fulfilled these criteria. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] Table 1 summaries the key information in these articles. The mean age of the previously reported patients with pulmonary angiosarcoma was 56.2 years, and in our cases, it was 64 years (range 54-74 years).…”
Pulmonary artery angiosarcoma is a rare malignant vascular tumor with an aggressive clinical course and a poor prognosis. Hemoptysis and shortness of breath have been reported as common clinical presentations. The exact clinicopathology is unknown. A tissue specimen obtained by percutaneous fine-needle aspiration cytology or open/thoracoscopic biopsy can confirm the diagnosis based on histopathological and immunohistochemical features. The differential diagnosis includes pulmonary thromboembolism, vascular malformations, and lung carcinoma. There is a paucity of literature describing this tumor, with only a few case reports available. There is also a lack of standardized guidelines for management, which further worsens the survival outcome. We report 3 cases of pulmonary artery angiosarcoma and review the recent literature.
“…First described in 1923 after reclassification of a primary cardiac tumor, pulmonary angiosarcomas (PAS) are classically found on the pulmonary arteries [ 2 , 3 ]. Subsequent literature and studies have been sparse, as PAS is frequently misdiagnosed due to a lack of defining symptoms as well as symptoms that more closely resemble more common diseases or conditions, such as thromboembolism [ 4 , 5 ]. Nevertheless, early detection and diagnosis have been reported, allowing for prompt resection of the tumor and increased odds of remission [ 6 , 7 ].…”
Pulmonary angiosarcomas (PAS) are rare malignant vascular tumors that due to their aggressive and metastatic nature, are often diagnosed at a late stage, resulting in a poorer prognosis. Here we present a 53-year-old male who was initially found to have recurring episodes of dyspnea and syncope, with initial workup showing bilateral saddle pulmonary embolisms on computerized tomography, presumed secondary to newly discovered atrial fibrillation with sinus node dysfunction. Further investigation over subsequent months and subsequent biopsy of a potential lung mass ultimately revealed pulmonary angiosarcoma of the spindle cell line. This case emphasizes findings in the current literature, which reveal the time between the onset of symptoms and definitive diagnosis ranges from two to six months, with a median survival time of seven months or two months, with solitary lesions or multiple lesions at the time of diagnosis, respectively. With the limited incidence of PAS, this case suggests benefits in the development of screening and detection criteria for earlier detection and treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.